Harold Rogers Prescription Drug Monitoring Training and Technical Assistance Program (2008 Competitive Grant Announcement)
The application period is now closed.
Developing and Enhancing Prescription Drug Monitoring Programs (FY 2008 Competitive Grant Announcement)
Frequently Asked Questions
The application period is now closed.
FY 2007 Prescription Drug Monitoring Program Grant Awards
Announcements:
BJA has released Frequently Asked Questions that address some common questions about the performance measures for this grant program.
Overview:
Beginning in FY 2002, Congress appropriated funding to the U.S. Department of Justice
to support the Prescription Drug Monitoring Program. Prescription monitoring
programs help prevent and detect the diversion and abuse of pharmaceutical controlled
substances, particularly at the retail level where no other automated information collection
system exists. States that have implemented prescription monitoring programs have the
capability to collect and analyze prescription data much more efficiently than states without such
programs, where the collection of prescription information requires the manual review of
pharmacy files, a time-consuming and invasive process.
The purpose of the Prescription Drug Monitoring Program is to enhance the capacity of
regulatory and law enforcement agencies to collect and analyze controlled substance prescription
data. The program focuses on providing help for states that want to establish a prescription drug
monitoring program. Resources are also available to states that wish to expand their existing programs.
Program objectives include:
- Building a data collection and analysis system at the state level.
- Enhancing existing programs' ability to analyze and use collected data.
- Facilitating the exchange of collected prescription data among states.
- Assessing the efficiency and effectiveness of the programs funded under this initiative.
PDMP Evaluation
In partnership with BJA, Simeone Associates released An Evaluation of Prescription Drug Monitoring Programs, which examines the effects of such programs on the
supply and abuse of prescription drugs. At the time of the study, 20 states had implemented and 23 states were in the process or designing or planning systems to
monitor the prescription and sale of drugs identified as controlled substances by the U.S. Drug Enforcement Administration. (Executive Summary)
Legislation: The Prescription Drug Monitoring Program was created by the FY 2002 U.S.
Department of Justice Appropriations Act (Public Law 107-77).
Funding: FY 2008 funding has not yet been determined. FY 2007 funding was $7.5 million.
Eligibility: Applicants are limited to the 50 U.S. states, the District of Columbia, Commonwealth of Puerto Rico, Northern Mariana Islands, Virgin Islands, Guam, and American Samoa
with legislation or regulations, either pending or in place, that (1) require the submission of dispensing data to a centralized database and (2) authorize or designate a state agency to implement
and administer the program. State governments that want to improve an existing prescription
drug monitoring program may apply for an enhancement award. States that want to apply for a planning grant do not need to have legislation or a regulation in place or pending.
How/When To Apply: BJA released the training and technical assistance solicitation on March 17, 2008, and applications are due May 15. BJA released the FY 2008 solicitation on October 29, 2007, and applications were due via Grants.gov on February 14, 2008.
Training/Technical Assistance:
Technical assistance for the BJA Prescription Drug Monitoring Program is provided by the
National Alliance for Model State Drug Laws (NAMSDL). NAMSDL provides states with necessary legislative and policy resources
to help them move forward in planning, implementing, or enhancing their PDMPs. Assistance to states includes maintaining a listserv for PDMP stakeholders, producing
and distributing a bimonthly PDMP update, tracking proposed bills and regulatory changes related to state PDMPs, and providing analysis of key information from states'
statutes and regulations regarding PDMPs.
For technical assistance, contact NAMSDL at (703) 836-6100 or visit NAMSDL's web site.
Additional technical assistance is available through the Justice Programs Office at American University.
If you need assistance with collecting data for BJA's performance measures, are interested in peer-to-peer site visits, or are interested in onsite technical assistance,
please fill out a request form.
BJA also provides funding to several other partners to support PDMP-related projects. The Integrated Justice Information Systems (IJIS) Institute is currently
working with BJA on a project related to information sharing between PDMPs. Phase I of the project involved defining the prescription monitoring information exchange
(PMIX) specifications to guide the implementation of systems that exchange data between states. For Phase II, IJIS implemented a pilot test between two states for
exchanging PDMP data. Based on the success of Phase II, work is now beginning on Phase III which will involve utilizing a hub server to centrally facilitate and
broker PMIX exchanges.
In FY 2006, BJA awarded a grant to the National Conference of State Legislators to educate state legislators and key legislative staff on the policy issues
associated with PDMPs. For more information about NCSL's work on PDMPs, visit www.ncsl.org/programs/cj/pdmp.htm.
In FY 2006, BJA also awarded a grant to the Addiction Technology Transfer Center (ATTC) National Office to develop resources to strengthen the linkages between
state PDMPs and state addiction treatment agencies. More information will be available soon.
Related Information:
Developing and Enhancing Prescription Drug Monitoring Programs (FY 2007 Competitive Grant Announcement)
Frequently Asked Questions
